Pharmaceuticals, Biotechnology and Life Sciences
Ablynx and Merck KGaA (Germany) have reported encouraging results from a study in psoriasis patients with the bi-specific Nanobody anti-IL-17A/F (M1095), via a clinical trials website (https://clinicaltrials.gov/NCT02156466).
Bpifrance and the Occitania region of Southern France have selected to support Sensorion, a biotechnology company specializing in the treatment…
Onxeo S.A., a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular…
NeuroVive Pharmaceutical will redirect its Taiwan-based subsidiary’s research resources and activities to the parent company NeuroVive Pharmaceutical.
ImmuPharma has provided details of patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus.
Vectura Group has triggered milestone receipt of $5 million from Novartis by reaching $512 million combined net sales of Seebri,…
Neovacs’s Scientific Advisory Board has recommended extension of the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018.
Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround
TxCell has moved into action to raise some money, as it wants to raise gross proceeds of about €11 million by issuing new shares with warrants attached.
The deal InnovaDerma had with PROS International Company of Korea to sell InnovaDerma products in a terrotiroy of S Korea, Japan, China and Russia has breaken apart, the UK based maker of hair and skin care products said on Wednesday.